Kronos Bio Inc (KRON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kronos Bio Inc (KRON) has a cash flow conversion efficiency ratio of -0.161x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.84 Million) by net assets ($79.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kronos Bio Inc (KRON) net asset quality to measure how much of total assets are equity-financed.
Kronos Bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Kronos Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Kronos Bio Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Kronos Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kronos Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Petros Petropoulos AEBE
AT:PETRO
|
-0.050x |
|
UAC Global Public Company Limited
BK:UAC
|
-0.063x |
|
Citizens Holding Company
NASDAQ:CIZN
|
0.018x |
|
Faraday Future Intelligent Electric Inc.
NASDAQ:FFAI
|
-3.661x |
|
Transcontinental Inc
TO:TCL-B
|
0.002x |
|
GCL Global Holdings Ltd Ordinary Shares
NASDAQ:GCL
|
-0.003x |
|
Gold Hydrogen Ltd
AU:GHY
|
-0.023x |
|
Grupo Ezentis S.A
MC:EZE
|
-0.677x |
Annual Cash Flow Conversion Efficiency for Kronos Bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kronos Bio Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see KRON market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $87.58 Million | $-65.44 Million | -0.747x | -51.25% |
| 2023-12-31 | $159.08 Million | $-78.58 Million | -0.494x | -32.83% |
| 2022-12-31 | $244.50 Million | $-90.93 Million | -0.372x | -8.83% |
| 2021-12-31 | $345.10 Million | $-117.92 Million | -0.342x | -319.59% |
| 2020-12-31 | $465.52 Million | $-37.91 Million | -0.081x | -112.53% |
| 2019-12-31 | $-23.20 Million | $-15.08 Million | 0.650x | -26.37% |
| 2018-12-31 | $-7.30 Million | $-6.44 Million | 0.883x | -- |
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more